DR. SARAH CRAWFORD

Who they are

Dr. Sarah Crawford is Professor of Genetics and Cancer Biology at Southern Connecticut State University — trained in retrovirology at Columbia and postdoctoral oncology research at Memorial Sloan Kettering Cancer Center.

Person

Sarah joined Southern Connecticut State University in 1993, when it was a regional public university well before its Carnegie R2 research classification. Before that, she did a postdoctoral fellowship at Memorial Sloan Kettering Cancer Center — one of the country's premier oncology institutions — which anchored her research identity in cancer biology. Her academic training ran through Princeton (Master's in Biochemistry and Molecular Biology) and Columbia University College of Physicians and Surgeons (Ph.D. in Virology, focused on retroviruses), a path that moved from molecular mechanisms toward translational cancer science. The through-line is deep disciplinary focus: she has spent her entire independent career at one institution, building expertise in genetics, tumor biology, breast cancer therapeutics, and glioblastoma rather than moving across roles or sectors. She posts occasionally on LinkedIn under her handle on cancer therapeutics and biology-chemistry collaboration, including cross-departmental breast cancer research at SCSU. Possibly — French language fluency points to interests or connections beyond the lab bench.

Company

The most recent development at Southern Connecticut State University is a $15 million NSF award received in July 2026 for QuantumCT, a statewide initiative to develop Connecticut's quantum workforce, with potential future investment up to $160 million and state support of $121 million. In October 2025, the university also received a $398,176 NSF grant through the EPIIC program to grow academic-industry partnerships, research capacity, and workforce development. The university reached a notable milestone in 2025, becoming Connecticut's first and only Carnegie-classified R2 research university. Internally, 2025 was turbulent: faculty and students across the Connecticut State Colleges and Universities system reported votes of no confidence and leadership departures, and food-service workers voted to authorize a potential strike in September 2025. Sandra Bulmer serves as interim president as of 2025, with a stated emphasis on innovation, research, and workforce development.

Market

Southern Connecticut State University is a public R2 research university founded in 1893, part of the Connecticut State University System, competing in various academic disciplines against a mix of private and public institutions — including Yale University, University of Connecticut, Quinnipiac University, University of New Haven, and Sacred Heart University in its core Connecticut market. In STEM and medical programs specifically, it competes with Columbia University, Harvard University, Yale University, and MIT in the broader Northeast. The university is leaning into differentiation through NSF-funded workforce initiatives in quantum technology and emerging STEM fields, collaborating with Yale and state agencies on technology commercialization.

Network

No direct edge data is available for Sarah Crawford's professional network. From the claims, she collaborates with colleagues in the Biology and Chemistry Department at SCSU on breast cancer therapeutics research — a cross-departmental partnership she has highlighted publicly.

How they likely show up

  • Joined SCSU in 1993 and has remained there through its transition to Carnegie R2 status → likely thinks in decade-long institutional arcs and values depth over mobility.
  • Ph.D. in retrovirology at Columbia → specialist orientation; she goes deep on a problem rather than broad across fields.
  • Postdoctoral work at Memorial Sloan Kettering Cancer Center → trained in a high-rigor, high-stakes clinical research environment before moving into academia, likely carries strong empirical standards.
  • Public writing signal is 'occasional' and focused on specific research topics (breast cancer therapeutics, biology-chemistry collaboration) → not a broad thought-leader poster; when she writes, it's tied to concrete research outputs.
  • Cross-departmental collaboration with Biology and Chemistry colleagues on breast cancer therapeutics → comfortable bridging disciplines, but the work stays anchored in the science rather than strategy or administration.

Conversation tips

  • → Ask about the biology-chemistry collaboration on breast cancer therapeutics she posted about — it's a concrete, named research direction she's clearly proud of.
  • → Reference the SCSU Carnegie R2 designation — she's been at the institution long enough to have watched that classification happen, and it directly validates decades of research investment.
  • → Don't conflate her retrovirology training with her current cancer biology work — she moved from virological mechanisms toward tumor biology, and the distinction matters to someone this specialized.
  • → Mention Memorial Sloan Kettering if the conversation touches on clinical translation — her postdoc there is the formative applied-research experience in her background.
  • → Possibly — French fluency could be a light opening if the conversation allows, but don't force it into a science discussion.

Toolbox

Openers

  • Open on the biology-chemistry collaboration she announced on LinkedIn — she's working across departments at SCSU on breast cancer therapeutics, which is an unusual cross-disciplinary move worth asking about.
  • Reference her retrovirology Ph.D. at Columbia and the pivot to cancer biology — the trajectory from retroviruses to tumor biology has a specific logic worth surfacing.
  • SCSU's July 2026 NSF QuantumCT award ($15 million, with up to $160 million in potential future investment) is the institution's biggest recent headline — ask how a research faculty member in cancer biology experiences that kind of institutional momentum.

Discovery questions

  1. How did your postdoctoral work at Memorial Sloan Kettering shape the research questions you've pursued at SCSU — what did clinical oncology research teach you that you couldn't have gotten in a pure academic lab?
  2. The biology-chemistry collaboration on breast cancer therapeutics at SCSU — is that a new direction for your lab, and what made cross-departmental research the right model for it?
  3. SCSU just earned its Carnegie R2 classification and landed a major quantum NSF award — as someone who joined in 1993, how has the research infrastructure and culture at the university shifted over that arc?

Avoid

Don't treat her as an institutional spokesperson for SCSU's quantum or STEM workforce initiatives — her expertise is in genetics and cancer biology, and pivoting the conversation toward QuantumCT or energy programs without grounding it in her research will signal you haven't done the work.

Make it yours

Tailor these openers to what you sell

These openers are generic. Sign in and tell Brief what you sell — it rewrites the hooks and questions around your pitch.

Sources

Brief on your next meeting?

Type any name. Get a structured pre-meeting brief in seconds.

Try Brief →

Generated by briefthecall.com from public web sources on August 3, 2026. Each claim is linked to its source above.

Automatically generated by AI from public sources. May be inaccurate or out of date. Remove or correct this profile →